http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112569338-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2020-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112569338-B |
| titleOfInvention | Application of TDFA in the preparation of medicines for preventing and/or treating ocular surface inflammatory diseases |
| abstract | The invention relates to the technical field of medicine, in particular to the application of TDFA in the preparation of medicines for preventing and/or treating ocular surface inflammatory diseases. This application provides an important supplement to the current mechanism research and drug targets of ocular surface inflammatory diseases, and broadens the research and application fields of TDFA. Compared with traditional anti-inflammatory drugs for ocular surface inflammatory diseases, TDFA targets NETs Formation process, at the same time, the use of local eye drops can non-invasively administer drugs, play a role through local penetration, and form a higher drug concentration in the local area, conveniently obtain better drug efficacy, and significantly reduce systemic circulation. The drug content reduces its potential systemic side effects and has higher safety. |
| priorityDate | 2020-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 288.